Optimization of production of anti-cancer vaccines based on dendritic cells

Cancer remains as one of the top killing diseases in first world countries. It’s not a single, but a set of various diseases for which different treatment approaches have been taken over the years. Cancer immunotherapy comes as a “new” breath on cancer treatment, taking use of the patients’ immune system to induce anti-cancer responses. Dendritic Cell (DC) vaccines use the extraordinary capacity of DCs’ antigen presentation so that specific T cell responses may be generated against cancer. In this work, we report the ex vivo generation of DCs from precursors isolated from clinical-grade cryopreserved umbilical cord blood (UCB) samples. After the thawing protocol for cryopreserved samples was optimized, the generation of DCs from CD14+ monocytes, i.e., moDCs, or CD34+ hematopoietic stem cells (HSCs), i.e, CD34-derived DCs, was followed and their phenotype and function evaluated. Functional testing included the ability to respond to maturation stimuli (including enzymatic removal of surface sialic acids), Ovalbumin-FITC endocytic capacity, cytokine secretion and T cell priming ability. In order to evaluate the feasibility of using DCs derived from UCB precursors to induce immune responses, they were compared to peripheral blood (PB) moDCs. We observed an increased endocytosis capacity after moDCs were differentiated from monocyte precursors, but almost 10-fold lower than that of PB moDCs. Maturation markers were absent, low levels of inflammatory cytokines were seen and T cell stimulatory capacity was reduced. Sialidase enzymatic treatment was able to mature these cells, diminishing endocytosis and promoting higher T cell stimulation. CD34-derived DCs showed higher capacity for both maturation and endocytic capacity than moDCs. Although much more information was acquired from moDCs than from CD34-derived DCs, we conclude the last as probably the best suited for generating an immune response against cancer, but of course much more research has to be performed.

Prevention of respiratory syncytial virus infections

Respiratory syncytial virus is the most important cause of viral lower respiratory illness in infants and children worldwide. By the age of 2 years, nearly every child has become infected with respiratory syncytial virus and re-infections are common throughout life. Most infections are mild and can be managed at home, but this virus causes serious diseases in preterm children, especially those with bronchopulmonary dysplasia. Respiratory syncytial virus has also been recognized as an important pathogen in people with immunossupressive and other underlying medical problems and institutionalizated elderly, causing thousands of hospitalizations and deaths every year. The burden of these infections makes the development of vaccines for respiratory syncytial virus highly desirable, but the insuccess of a respiratory syncytial virus formalin-inactivated vaccine hampered the progress in this field. To date, there is no vaccine available for preventing respiratory syncytial virus infections, however, in the last years, there has been much progress in the understanding of immunology and immunopathologic mechanisms of respiratory syncytial virus diseases, which has allowed the development of new strategies for passive and active prophylaxis. In this article, the author presents a review about novel approaches to the prevention of respiratory syncytial virus infections, such as: passive immunization with human polyclonal intravenous immune globulin and humanized monoclonal antibodies (both already licensed for use in premature infants and children with bronchopulmonary dysplasia), and many different vaccines that are potential candidates for active immunization against respiratory syncytial virus.

Critical analysis of old and new vaccines against N. meningitidis serogroup C, considering the meningococcal disease epidemiology in Brazil

Worldwide, the impact of meningococcal disease is substantial, and the potential for the introduction and spread of more virulent strains of N. meningitidis or strains with increased resistance to current antibiotics causes concern, making prevention essential. OBJECTIVES: Review the indications for meningococcal disease vaccines, considering the epidemiological status in Brazil. METHODS: A critical literature review on this issue using the Medline and Lilacs databases. RESULTS: In Brazil, MenB and MenC were the most important serogroups identified in the 1990s. Polysaccharide vaccines available against those serogroups can offer only limited protection for infants, the group at highest risk for meningococcal disease. Additionally, polysaccharide vaccines may induce a hypo-responsive state to MenC. New meningococcal C conjugate vaccines could partially solve these problems, but it is unlikely that in the next few years a vaccine against MenB that can promote good protection against multiple strains of MenB responsible for endemic and epidemic diseases will become available. CONCLUSIONS: In order to make the best decision about recommendations on immunization practices, better quality surveillance data are required. In Brazil, MenC was responsible for about 2,000 cases per year during the last 10 years. New conjugate vaccines against MenC are very effective and immunogenic, and they should be recommended, especially for children less than 5 years old. Polysaccharide vaccines should be indicated only in epidemic situations and for high-risk groups. Until new vaccines against MenC and MenB are available for routine immunization programs, the most important measure for controlling meningococcal disease is early diagnosis of these infections in order to treat patients and to offer chemoprophylaxis to contacts.

Engineering modular viral scaffolds for targeted bacterial population editing

Bacteria are central to human health and disease, but existing tools to edit microbial consortia are limited. For example, broad-spectrum antibiotics are unable to precisely manipulate bacterial communities. Bacteriophages can provide highly specific targeting of bacteria, but assembling well-defined phage cocktails solely with natural phages can be a time-, labor- and cost-intensive process. Here, we present a synthetic biology strategy to modulate phage host ranges by engineering phage genomes in Saccharomyces cerevisiae. We used this technology to redirect Escherichia coli phage scaffolds to target pathogenic Yersinia and Klebsiella bacteria, and conversely, Klebsiella phage scaffolds to target E. coli by modular swapping of phage tail components. The synthetic phages achieved efficient killing of their new target bacteria and were used to selectively remove bacteria from multi-species bacterial communities with cocktails based on common viral scaffolds. We envision this approach accelerating phage biology studies and enabling new technologies for bacterial population editing.

High-level of viral genomic diversity in cervical cancers: a Brazilian study on human papillomavirus type 16

Invasive cervical cancer (ICC) is the third most frequent cancer among women worldwide and is associated with persistent infection by carcinogenic human papillomaviruses (HPVs). The combination of large populations of viral progeny and decades of sustained infection may allow for the generation of intra-patient diversity, in spite of the assumedly low mutation rates of PVs. While the natural history of chronic HPVs infections has been comprehensively described, within-host viral diversity remains largely unexplored. In this study we have applied next generation sequencing to the analysis of intra-host genetic diversity in ten ICC and one condyloma cases associated to single HPV16 infection. We retrieved from all cases near full-length genomic sequences. All samples analyzed contained polymorphic sites, ranging from 3 to 125 polymorphic positions per genome, and the median probability of a viral genome picked at random to be identical to the consensus sequence in the lesion was only 40%. We have also identified two independent putative duplication events in two samples, spanning the L2 and the L1 gene, respectively. Finally, we have identified with good support a chimera of human and viral DNA. We propose that viral diversity generated during HPVs chronic infection may be fueled by innate and adaptive immune pressures. Further research will be needed to understand the dynamics of viral DNA variability, differentially in benign and malignant lesions, as well as in tissues with differential intensity of immune surveillance. Finally, the impact of intralesion viral diversity on the long-term oncogenic potential may deserve closer attention.

ETIOLOGÍA E IMPORTANCIA ECONÓMICA DE UNA NUEVA ENFERMEDAD VIRAL DE BATATA EN LA PROVINCIA DE CÓRDOBA

La batata se ubica en el séptimo lugar como cultivo destinado a la alimentación humana, y en el quinto luego de arroz, trigo, maíz y mandioca. Globalmente, existen 8 millones de hectáreas plantadas con batata y, aproximadamente el 95% de esa superficie se ubica en más de un centenar de países en desarrollo. En Argentina, la región pampeana (Buenos Aires, Córdoba y Santa Fe) y el NEA representan el 83% de la superficie plantada. Córdoba y Buenos Aires constituyen las principales provincias productoras. A pesar de su importancia potencial en la alimentación humana y animal, como producto exportable y para industrialización, se viene registrando una marcada reducción en el área cultivada con esta hortícola y, entre las causas más relevantes que determinan este fenómeno, se encuentran las enfermedades virales. Históricamente estas patologías han sido la principal limitante en la producción de este cultivo en Argentina y, especialmente en Córdoba. Recientemente y, tras brindar solución al grave problema ocasionado por el “enanismo clorótico” (Sweet potato chlorotic dwarf disease), virosis que afectó al cv Morada INTA en la década del 90, se observó, en nuestra provincia, la aparición de una severa sintomatología viral en lotes de producción implantados con el cv Arapey INIA, genotipo de creciente difusión en el cultivo por sus buenas características agronómicas. En virtud de dicha sintomatología, se sugiere que en la nueva patología viral se halla involucrado más de un agente etiológico y que la misma produce daños económicos en la producción de Arapey INIA. Por otra parte, la identificación de el/los virus presentes en la nueva patología es el primer eslabón para la búsqueda de resistencia a los mismos. Se supone, además, que, en germoplasma selecto de batata existen fuentes de resistencia a el/los virus involucrados y, que, al menos uno de los agentes patógenos de esta virosis de Arapey INIA, es transmitido por moscas blancas. Se propone, como paso inicial para el control de la nueva etiología: caracterizar biológica, serológica y molecularmente a el/los virus involucrados en ella; preparar reactivos de diagnóstico para los mismos y evaluar la gravedad de esta virosis a través de la estimación de su incidencia, prevalencia y severidad y de los daños que provoca sobre los componentes de rendimiento, en zonas productoras de la provincia de Córdoba. Por otra parte y, debido a que una de las principales formas de control de estas enfermedades es a través del empleo de germoplasma resistente y, considerando que la mayoría de los cultivares comerciales de batata, incluído Arapey INIA poseen escasa variabilidad genética por ser monoclonales, se pretende explorar molecularmente para genes de resistencia en aproximadamente 30 genotipos (clones) promisorios procedentes de la EEA INTA San Pedro ( Bs.As.), empleados como parentales en policruzamientos, además de hacerlo en el genotipo bajo estudio (Arapey INIA).

Enfermedades de origen viral u ocasionadas por mollicutes en los nuevos escenarios del cultivo en la provincia de Córdoba.

Argentina es el tercer exportador mundial de maíz luego de Estados Unidos y Brasil. La estimación de la campaña 2009/10 indica que la producción mundial de maíz alcanzaría los 832,37 millones de toneladas, cerca de 23 millones de toneladas más que lo cosechado durante la campaña anterior y 21 millones de toneladas mas que lo cosechado en la campaña récord de 2007/08 (USDA, 2010). La cosecha de maíz 2009/10 en Argentina sería récord, llegando a los 22,5 millones de toneladas lo que significaría un incremento de 53% respecto de la campaña anterior, igualando el récord de la campaña 2006/07. El aumento de la potencialidad de rendimiento se concibe desde un cultivo sin incidencia de enfermedades. La predicción de la ocurrencia y del riesgo de daño asociado a las enfermedades de los cultivos a gran escala, la determinación del riesgo de distribución de pestes exóticas o emergentes en la agricultura sustentable, la evaluación de riesgo/beneficio del control biológico y la evaluación de enfermedades asociadas con el calentamiento global o el cambio de prácticas culturales son tópicos importantes en la ciencia agropecuaria moderna. Las enfermedades del maíz, en especial las producidas por virus y mollicutes se han incrementado en los últimos años debido, entre otras causas, al cultivo continuo desde el norte del país y países vecinos desde donde migran los vectores, a los cultivares de alto rendimiento que en muchos casos son susceptibles a estos patógenos y en gran medida a los cambios climáticos globales que generan que virosis de zonas tropicales y subtropicales se extiendan a zonas templadas. El principal enfoque para el control es el conocimiento del ciclo epidemiológico de la enfermedad ubicado para cada ambiente. En este marco es que desde el Departamento de Graduados de la Fac. de Cs. Agropecuarias, junto con la Secretaría de Extensión surgió la necesidad de la transferencia de los resultados de la investigación. Los conocimientos adquiridos en investigación hasta el presente, en toda la extensión de la Provincia de Córdoba, servirán a profesionales asesores, empresas semilleras y de insumos agropecuarios, productores y estudiantes próximos a graduarse a conocer estas enfermedades, sus vectores, las condiciones predisponentes y tener acceso a información actualizada para lograr su manejo con medidas preventivas desde el momento de la compra de los insumos agropecuarios, el sistema de labranza y de las fechas de siembra. Entrenar al productor para que adquiera esta habilidad le permitirá escapar a pérdidas de hasta 60% del lote, como son las producidas en la Provincia por algunas virosis como el Mal de Río Cuarto (March et al., 1993, Gaceta agronómica 76: 384), o pérdidas no perceptibles pero reales, de 14% en plantas con esta enfermedad respecto a plantas sanas (Ornaghi et a., 1995, IX J. Fitosanitarias Argentinas: 84). Otras virosis, como el mosaico común, no producen grandes epidemias sino son incidiosas, están presentes todos los años con pérdidas de producción a niveles tan significativos como 5,5 qq/ha e incidencias de hasta 44% en la Provincia (Lenardón y Giolitti, 1999, Proyecto de Investig. en Fitovirología INTA-JICA) y requiere certificación sanitaria para la exportación del grano pues se transmite por semilla. Por su parte, mollicutes emergentes como el Corn stunt spiroplasma, se han detectado en Córdoba con incidencias de 61% en lotes de Justiniano Posse y de 80% en Sarmiento, habiéndose detectado en la campaña 2009/10 en 4 localidades de la Provincia. Virosis re-emergentes como el MCMV, que produce necrosis letal del maíz en sinergismo con otras virosis, han hecho su reaparición con niveles de hasta 18% de infección. Reconocer sus síntomas y conocer las formas de dispersión y transmisión permitirá al profesional y al productor la evaluación del problema y tomar medidas de prevención y manejo de estas enfermedades para lograr los rendimientos esperados.

Molecular biological analysis of dynamic interactions between influenza viruses and host cells : host cell proteomes and viral replication dynamics

Magdeburg, Univ., Fak. für Verfahrens- und Systemtechnik, Diss., 2011

Quantitative method of viral pollution determination for large volume of water using ferric hydroxide gel impregnated on the surface of glassfibre cartridge

Quantitative method of viral pollution determination for large volume of water using ferric hydroxide gel impregnated on the surface of glassfibre cartridge filter. The use of ferric hydroxide gel, impregnated on the surface of glassfibre cartridge filter enable us to recover 62.5% of virus (Poliomylitis type I, Lsc strain) exsogeneously added to 400 liters of tap-water. The virus concentrator system consists of four cartridge filters, in which the three first one are clarifiers, where the contaminants are removed physically, without significant virus loss at this stage. The last cartridge filter is impregnated with ferric hydroxide gel, where the virus is adsorbed. After the required volume of water has been processed, the last filter is removed from the system and the viruses are recovered from the gel, using 1 liter of glycine/NaOH buffer, at pH 11. Immediately the eluate is clarified through series of cellulose acetate membranes mounted in a 142mm Millipore filter. For the second step of virus concentration, HC1 1N is added slowly to the eluate to achieve pH 3.5-4. MgC1, is added to give a final concentration of 0.05M and the viruses are readsorbed on a 0.45 , porosity (HA) cellulose acetate membrane, mounted in a 90 mm Millipore filter. The viruses are recovered using the same eluent plus 10% of fetal calf serum, to a final volume of 3 ml. In this way, it was possible to concentrate virus from 400 liters of tap-water, into 1 liter in the first stage of virus concentration and just to 3 ml of final volume in a second step. The efficiency, simplicity and low operational cost, provded by the method, make it feasible to study viral pollution of recreational and tap-water sources.

The viral nature of Toddia França, 1912

Toddia França, 1912 under the light microscope occurs as inclusion corpuscles in the cytoplasm of erythrocytes of cold-blooded vertebrates sometimes accompanied by crystalloid bodies. Its position among the protozoans or the viruses has been discussed by some authors, but remained unclear. To elucidate this problem we studied Toddia from a Brazilian frog (Leptodactylus ocellatus) by electron microscopy. In the cytoplasm of the infected cells we found no protozoan, but rather virus-like particles often hexagonal in outline, averaging 195 nm excluding their two involving membranes, and presenting a central area of variable electron density. Particles at different stages of development were generally found around or on area lighter density than the cytoplasm. which resembled a virus synthesis site. At high magnification, the nuclear or cytoplasmic crystals allied to Toddia resembled the crystalline lattice of the inclusion bodies associated with the polyhedrosis viruses and poxviruses from insects, of the capsules of granulosis viruses and of other protein crystals in ultrathin sections. Cytochemical tests in Toddia corpuscles displayed exclusively the presence of deoxyribonucleic acid. These findings indicate that Toddia is not a protozoan and demonstrate that it is in all probability a viral inclusion corpuscle. Taking into account the nucleic acid type found in its structure (DNA) and the hexagonal shape usually shown in ultrathin sections by its component particles, which have a cytoplasmic site of synthesis and assembly, we tentatively relate Toddia with the so-called "Icosahedral Cytoplasmic Deoxyriboviruses". We believe that the present paper gives the first report of virus-like particles in L. ocellatus.

Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial.

OBJECTIVE: Tuberculosis (TB) is highly prevalent among HIV-infected people, including those receiving combination antiretroviral therapy (cART), necessitating a well tolerated and efficacious TB vaccine for these populations. We evaluated the safety and immunogenicity of the candidate TB vaccine M72/AS01 in adults with well controlled HIV infection on cART. DESIGN: A randomized, observer-blind, controlled trial (NCT00707967). METHODS: HIV-infected adults on cART in Switzerland were randomized 3 : 1 : 1 to receive two doses, 1 month apart, of M72/AS01, AS01 or 0.9% physiological saline (N = 22, N = 8 and N = 7, respectively) and were followed up to 6 months postdose 2 (D210). Individuals with CD4⁺ cell counts below 200 cells/μl were excluded. Adverse events (AEs) including HIV-specific and laboratory safety parameters were recorded. Cell-mediated (ICS) and humoral (ELISA) responses were evaluated before vaccination, 1 month after each dose (D30, D60) and D210. RESULTS: Thirty-seven individuals [interquartile range (IQR) CD4⁺ cell counts at screening: 438-872 cells/μl; undetectable HIV-1 viremia] were enrolled; 73% of individuals reported previous BCG vaccination, 97.3% tested negative for the QuantiFERON-TB assay. For M72/AS01 recipients, no vaccine-related serious AEs or cART-regimen adjustments were recorded, and there were no clinically relevant effects on laboratory safety parameters, HIV-1 viral loads or CD4⁺ cell counts. M72/AS01 was immunogenic, inducing persistent and polyfunctional M72-specific CD4⁺ T-cell responses [medians 0.70% (IQR 0.37-1.07) at D60] and 0.42% (0.24-0.61) at D210, predominantly CD40L⁺IL-2⁺TNF-α⁺, CD40L⁺IL-2⁺ and CD40L⁺IL-2⁺TNF-α⁺IFN-γ⁺]. All M72/AS01 vaccines were seropositive for anti-M72 IgG after second vaccination until study end. CONCLUSION: M72/AS01 was clinically well tolerated and immunogenic in this population, supporting further clinical evaluation in HIV-infected individuals in TB-endemic settings.

Single-cell gene-expression profiling reveals qualitatively distinct CD8 T cells elicited by different gene-based vaccines.

CD8 T cells play a key role in mediating protective immunity against selected pathogens after vaccination. Understanding the mechanism of this protection is dependent upon definition of the heterogeneity and complexity of cellular immune responses generated by different vaccines. Here, we identify previously unrecognized subsets of CD8 T cells based upon analysis of gene-expression patterns within single cells and show that they are differentially induced by different vaccines. Three prime-boost vector combinations encoding HIV Env stimulated antigen-specific CD8 T-cell populations of similar magnitude, phenotype, and functionality. Remarkably, however, analysis of single-cell gene-expression profiles enabled discrimination of a majority of central memory (CM) and effector memory (EM) CD8 T cells elicited by the three vaccines. Subsets of T cells could be defined based on their expression of Eomes, Cxcr3, and Ccr7, or Klrk1, Klrg1, and Ccr5 in CM and EM cells, respectively. Of CM cells elicited by DNA prime-recombinant adenoviral (rAd) boost vectors, 67% were Eomes(-) Ccr7(+) Cxcr3(-), in contrast to only 7% and 2% stimulated by rAd5-rAd5 or rAd-LCMV, respectively. Of EM cells elicited by DNA-rAd, 74% were Klrk1(-) Klrg1(-)Ccr5(-) compared with only 26% and 20% for rAd5-rAd5 or rAd5-LCMV. Definition by single-cell gene profiling of specific CM and EM CD8 T-cell subsets that are differentially induced by different gene-based vaccines will facilitate the design and evaluation of vaccines, as well as enable our understanding of mechanisms of protective immunity.

Detection of viral infection by immunofluorescence in formalin-fixed tissues, pretreated with trypsin

The presence of viral antigen in sections from formalin-fixed and paraffin-embedded human tissues was demonstrated by trypsin digestion followed by direct or indirect immunofluorescence. The specimens may be used for retrospective diagnosis. The immunofluorescence technique has to be adapted to the suspected virus infection on the basis of previous histopathology study. Variations of trypsin concentration time and temperature of incubation, expose different viral antigens and have to be previously tested for each unknown system. For measles virus detection in lung a stronger digestion has to be applied as compared to adenovirus or respiratory disease viruses in the same tisue. Flavivirus in liver tissue needs a weaker digestion. The reproducibility of the method makes it useful as a routine technique in diagnosis of virus infection.